Peginterferon SA - Beijing Kawin Technology

Drug Profile

Peginterferon SA - Beijing Kawin Technology

Alternative Names: PEG-IFN-SA; Pegylated interferon variant SA - Beijing Kawin Technology; Pegylated Recombinant Consensus Interferon Variant Solution - Beijing Kawin Technology

Latest Information Update: 02 Nov 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Beijing Kawin Technology Share-Holding
  • Class Antivirals; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hepatitis C

Most Recent Events

  • 01 Oct 2012 Phase-II clinical trials in Hepatitis C (Treatment-naive, Combination therapy) in China (SC) (NCT01908335)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top